* Biogen CEO: “overall, we maintain our global market share in multiple sclerosis (treatments)”
* Biogen CEO: global Tecfidera Q2 revenues of $1.1 billion is a 13% increase versus the prior year; about half of that growth was driven by volume
* Biogen CEO assumes continued strong Spinraza growth in U.S. patients, but expects growth to slow as patients move from loading dose to maintenance therapy
